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Background: Adrenaline autoinjectors (AAIs) are prescribed to facilitate the intramuscular 
administration of adrenaline in patients diagnosed with life-threatening anaphylaxis. This pilot 
study investigated the injection and functional properties of two AAIs (deploying different 
delivery systems) under standard conditions, after dynamic and mechanical stresses, and in 
the presence of denim.
Methods: The differences between a cartridge-based AAI (EpiPen® Junior) and a syringe-based 
AAI (Anapen® Junior) were assessed using three sets of tests. Test 1: under standard conditions, 
the injection depth and dose were measured in ballistic gelatine (a validated tissue simulant). Test 
2: before the safety cap removal and activation forces were measured, AAIs were subjected to 
either of two preconditioning tests: 1) free-fall drop test; or 2) static load (ie, 400 N, equivalent 
to 40 kg weight) test; or 3) no preconditioning. Test 3: under standard conditions, injection prop-
erties into ballistic gelatine in the presence and absence of denim were investigated. Statistical 
analyses were performed using the Student’s t-test or Welch’s test.
Results: The maximum depth of delivery was significantly greater with cartridge AAI (n = 4, 
mean 21.09 ± 2.54 mm) than with syringe AAI (n = 5; mean 11.64 ± 0.80 mm; P = 0.003). After 
2.5 seconds, cartridge AAI (n = 4) discharged significantly more dose than syringe AAI (n = 3; 
74.3% versus 25.7% of total dose; P = 0.001). Both cartridge and syringe AAI withstood the 
free-fall drop test, but almost all devices failed to activate following the static load test. Under 
standard conditions, significantly less force was required to remove the safety cap of cartridge 
AAI than syringe AAI (both n = 15; mean 9.56 ± 2.36 N versus 20.23 ± 6.61 N, respectively; 
P , 0.001), but a significantly greater activation force was required for cartridge AAI than 
syringe AAI (mean 23.01 ± 3.96 N versus 8.06 ± 0.51 N, respectively; P , 0.001). The presence 
of denim did not alter the activation force or effective needle length of either of the AAIs.
Conclusion: Cartridge AAI appears significantly more capable of consistently and rapidly 
delivering a clinically relevant dose of intramuscular adrenaline than syringe AAI. However, 
both devices showed shortcomings in their ability to sustain mechanical stress similar to that 
which is likely over their shelf life, and as such, may not be fit for life-saving purpose.
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Background
Rapid intramuscular (i.m.) adrenaline administration is the acknowledged first-line 
therapy for the emergency treatment of anaphylaxis, in both hospital and community 
settings.1−3 Because most anaphylactic reactions occur outside of a health care setting,4 
adrenaline autoinjectors (AAIs) are widely prescribed to patients diagnosed with Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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anaphylaxis or those who are at serious risk of anaphylaxis as 
a result of their allergic status. The AAI should be carried by 
the patient at all times, providing immediate access to adrena-
line during an acute anaphylactic attack, when emergency 
medical care is otherwise unavailable.
Worryingly, there is significant anecdotal evidence and 
safety data to suggest that AAIs do not always perform 
adequately and can misfire.5–7 The design of currently 
available AAIs has not changed significantly in decades. 
Although the original AAI, EpiPen® – a cartridge-based 
system – was deemed suitable to ensure the force of injection 
was sufficient to achieve i.m. penetration, Anapen® (based 
on a design developed by Owen Mumford named Autoject 
Mini®) deploys a syringe-based modified insulin injection 
device, originally designed for subcutaneous administra-
tion of insulin for use in elective situations. Therefore, it 
is surprising that there are no criteria currently in place, 
including International Organization of Standards or other 
regulatory requirements,8 to benchmark the performance of 
AAIs under standard conditions – as there are for insulin pen-
injectors9 – nor tests in routine use to measure the potential 
effects of everyday wear and tear on AAIs.
This pilot study investigated the functionality and robust-
ness of two currently available AAIs in Europe that deploy 
different drug delivery systems: EpiPen® Junior (referred to 
herein as cartridge AAI) and Anapen® Junior (referred to 
herein as syringe AAI). The main objectives of this study 
were to assess the differences between the two delivery sys-
tems in terms of the injection depth and dose delivered into 
ballistic gelatine, and to determine the effects of a free-fall 
drop test, static load test, and the presence of denim on the 
performance of these devices.
Methods
In this study, the two AAI devices used for testing were 
designated cartridge AAI (EpiPen® Junior containing 0.15 mg 
adrenaline; batch numbers 0000105507 and 0000106991; 
ALK-Abelló, Berkshire, UK) and syringe AAI (Anapen® 
Junior containing 0.15 mg adrenaline; batch GWR 26122010; 
Lincoln Medical Ltd, Salisbury, UK), reflecting the type of 
delivery system deployed.
Several performance tests were carried out: an   injection 
test, to assess the requirement of AAIs to deliver an i.m. 
injection of adrenaline; a stress test, to determine the ability 
of the AAIs to resist breakage or malfunction due to the 
application of eccentric force or falls; and an effective 
needle-length test, to evaluate the consistency of the AAIs 
to perform under standard conditions and in a ‘real-world’ 
model by injection through denim.
In the first round of tests, 15 of each of the AAIs were 
subjected to several tests to examine the injection proper-
ties (ie, injection depth [in ballistic gelatine], injection dose 
as measured by the volume injected into ballistic gelatine, 
and effective needle length [in air]). Effective needle length 
reflects the potential depth of penetration of the needle itself; 
for example, a needle that is bent or kinked may not achieve 
the same depth of injection as a straight needle, which may 
in turn affect the injection properties or results.
In the second round of tests, 45 of each of the AAIs were 
subjected to one of three conditions: 1) preconditioning – free-
fall drop (n = 15), 2) preconditioning – static load (n = 15), or 
3) no preconditioning – room temperature and standard atmo-
spheric pressure (ie, control; n = 15), followed by a series of 
functionality tests to examine the safety cap removal force and 
activation force. The two preconditioning tests, free-fall drop 
test and static load test, were used to mimic real-life situations 
of being dropped and sat/stood on, respectively.
In the last round of tests, 10 of each of the AAIs were 
subjected to a series of tests to measure activation force and 
effective needle length after activation into ballistic gelatine 
in the presence or absence of denim.
injection test
injection depth
The depth of the injected solution into ballistic gelatine 
(a validated tissue simulant)10,11 was tested by analysing a series 
of photographs taken for up to 10 seconds (±0.5 seconds) after 
activation, using an application programmed in Matlab© 
(version R2008A; The Mathworks Inc., Natick, MA). To 
  visualize the ejected volume, the transparent medication in 
each device was colored with 0.05 mL of ink. Due to variations 
in device construction, a different preparation method for 
each of the two devices was adopted (see Figure 1). Instead 
of 0.3 mL (±10%) transparent medication in the unprepared 
device, the total quantity of colored solution was 0.35 mL 
(±20%) in the prepared test devices.
The maximum injection depth reached is a composite of 
the actuating position (affected by the force being applied 
by the operator to activate only the cartridge device, thereby 
compacting subcutaneous tissue), effective (exposed) needle 
length, and injection depth of the medication (as measured 
in the ballistic gelatine).
injected dose, as measured by injected  
volume over time (in ballistic gelatine)
By assessing key timepoints over the filmed sequence, the 
two-dimensional area of the injected solution was analyzed 
using a Matlab application. For each frame of the sequence, Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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(A) Cartridge AAI 
Step 1:  A 6 mm hole was drilled through the outer housing of the pen. 
Step 2:  0.5 mL ink was injected sideways through the plunger stopper via a needle 
(25G needle) and syringe. 
Step 3:  The volume of added ink was confirmed by weighing the device before 
              and after filling.  
Figure 1 Preparation of cartridge AAi (A) and syringe AAi (B) devices for the ballistic gelatine test.
Abbreviation: AAi, adrenaline autoinjector.
(B) Syringe AAI preparation 
Step 1:  The needle/protection cap was removed and 0.5 mL ink was injected via a 
needle (22G needle that fits over the 27G needle of the syringe AAI) and 
syringe. 
Step 2:  The volume of added ink was confirmed by weighing the device before
 and after filling. 
the area of the colored medication was converted into pixels 
by digital image processing. Based on the number of pixels, 
the injected dose was calculated.
Key device properties measured and noted
After testing of the activation force, the effective needle 
length as determined by the exposed needle using a caliper, 
and the diameter of the needle bore, were noted.
Preparation of the ballistic gelatine blocks
Ballistic gelatine has been used as a tissue simulant for 
research purposes since the 1960s.10,11 The ballistic gela-
tine blocks were prepared according to the manufacturer’s 
instructions (Gelita Gelatine, Typ Ballistic 3; Lot: 73211). 
A plastic box (transparent polypropylene; 60 mm × 60 mm) 
was filled with the gelatine fluid (170 mL), and stored for 
a minimum of 48 hours at 4°C. Because the temperature of Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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the gelatine may affect its hardness, all blocks were stored at 
room temperature and standard pressure for at least 24 hours 
before use. The hardness of each gelatine block was checked 
and described using the Bloom index (score range 50–300), 
confirming that the tests were performed with similar blocks. 
In order to avoid damage to the surface of the gelatine by 
autoinjectors that have a higher activation force, a top layer 
of a 0.5 mm polypropylene foil (with a small 2 mm central 
hole) was placed on top of each ballistic cube.
Preconditioning – stress tests
Dynamic impact (free-fall drop test)
To assess the robustness of the device, and to mimic real-life 
situations of accidentally dropping the device, each brand of 
autoinjector was subjected to the drop test. The devices were 
dropped three times in free fall from a height of 1 m onto a 
hard, concrete plate, once horizontally and twice vertically, 
the autoinjector being rotated between the two vertical drops. 
In order to standardize the test process, the autoinjectors were 
guided by a plastic pipe.
Static load
To mimic real-life situations such as accidentally sitting or 
stepping on the device, both autoinjectors were subjected 
to the static load test. Each autoinjector was secured verti-
cally onto the Zwick equipment (Zwick GmbH & Co, Ulm, 
Germany) via an adapter before a static weight of 400 N, 
equivalent to 40 kg (ie, the approximate weight of a child), 
was automatically loaded for 10 seconds.
Functionality tests
Safety cap removal force
Inherent within the design of syringe AAI are two caps: 
1) a protection cap (that covers the needle) and 2) a safety cap 
(that prevents accidental firing); whereas the cartridge AAI only 
has one cap (a safety cap). Therefore, syringe AAI requires an 
extra operational step to remove both caps before the device 
can be activated, compared with cartridge AAI.12 It is important 
that the safety cap can still be removed easily and without 
extra force after it has been dropped or when a load has been 
applied. In this study, the force required to pull off the caps was 
tested and compared using Zwick© equipment (Type: BT01-
FRO.5TND.14; serial no: 185124/2008; Zwick Roell) and a 
specially designed adapter to hold the cap (see Figure 2).
Activation force
In real-life situations, the technique required to activate 
cartridge AAI is different from that required for syringe 
AAI (ie, a swinging activation versus thumb activation, 
respectively). However, in this study, both autoinjectors 
were activated using the same methodology. After each 
of the autoinjectors was secured vertically onto the Zwick 
equipment (via exchangeable adapters that incorporated the 
different cartridge- or syringe-based systems), the device was 
activated – ejecting the medication in air or, in the case of 
the denim series of experiments, into ballistic gelatine placed 
at the bottom of the equipment – and the activation force 
recorded.
effect of denim on activation force  
and effective needle length
Secured vertically onto the Zwick equipment via an adapter, 
each autoinjector was fired into ballistic gelatine in the 
presence or absence of a piece of denim (a double seam of 
Levi’s blue jeans). The activation force was recorded, and the 
effective (exposed) needle length was measured by a caliper 
after the device was removed from the ballistic gelatine. 
In addition, the exposed needle was inspected visually.
Statistical analyses
Data were described as mean ± standard deviation. Due 
to the number of test devices assessed in this pilot study, 
intergroup differences were compared using the t-test or 
the Welch’s test (safety cap removal and activation force; 
injection depth and delivered dose, as appropriate depending 
on the statistical preconditions, with statistical significance 
when P , 0.05).
Results
injection depth and dose delivered – 
standard conditions
effect on injection depth
Under standard conditions, the maximum injection 
depth of cartridge AAI (n = 4; mean 21.09 ± 2.54 mm) 
was significantly greater than syringe AAI (n = 5; mean 
11.64 ± 0.80 mm; P , 0.001) (see Figures 3 and 4).
injection dose (into ballistic gelatine)
After 2.5 seconds, cartridge AAIs had discharged signifi-
cantly more dose (n = 4; mean 0.26 ± 0.04 mL [74.3% of 
total dose]) than syringe AAIs (n = 3; mean 0.09 ± 0.02 mL 
[25.7% of total dose]; P , 0.01) (see Figure 5). Although 
patients are instructed to hold the AAI for 10 seconds after 
device activation, results from this study show that with 
cartridge AAI, the mean injection volume had plateaued after 
just 2.5 seconds, but not with syringe AAI (data not shown). Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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Physical properties of layered gelatine blocks hampered 
interpretation of data beyond 2.5 seconds, as this was the 
timepoint at which maximum delivery of dose was achieved 
with syringe AAI (Figure 4).
effective needle length and needle bore diameter
Under standard conditions, the mean effective needle length 
of cartridge AAI after activation was significantly longer 
than syringe AAI (both n = 15; 13.13 ± 0.208 mm and 
8.02 ± 0.769 mm, respectively; P , 0.001), and the needle 
bore diameter is larger (ie, 22 gauge versus 27 gauge needles, 
respectively) (see Figure 6).
effect of preconditioning
Overall, the preconditioning tests demonstrated that both 
cartridge AAI and syringe AAI were able to withstand a 
free-fall drop test from 1 m onto concrete, although in one 
free-fall test with cartridge AAI front ahead, the device was 
rendered nonsterile, as the needle pierced through the rub-
ber cap and the needle tip was damaged (Table 1). However, 
neither of the AAIs was able to withstand the static load test, 
as signs of damage to the outer housing on visual inspection 
were noted (Table 1).
effect on safety cap removal force
Under control conditions (ie, without preconditioning), 
no significant difference was found between the removal 
force of the protection cap and the safety cap of syringe 
AAI (P = 0.08). Therefore, only the removal force of the 
safety cap for syringe AAI has been used in subsequent 
comparisons. When comparing the safety cap removal force, 
significantly less force was required to remove the cartridge 
A)
B)
C)
Figure 2 The Zwick© equipment measuring the safety cap removal force of syringe adrenaline autoinjector (AAi) (A) and cartridge AAi (B) with the specially designed 
adapter (C).Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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AAI safety cap than the syringe AAI safety cap (P , 0.001)   
(see Table 2).
After preconditioning with a free-fall drop test, the mean 
safety cap removal force for both autoinjectors was not altered 
significantly compared with its respective controls (Table 2). 
However, after preconditioning with a static load, the mean 
safety cap removal force for cartridge AAI was increased 
approximately fourfold (P , 0.001), whereas there was no sig-
nificant change with syringe AAI (P = 0.633) (see Table 2).
effect on activation force
Without preconditioning, the activation force for cartridge 
AAIs (n = 15; hand activation) was greater than for syringe 
AAIs (n = 15; thumb activation) (mean 23.01 ± 3.96 N versus 
8.06 ± 0.51 N, respectively; P , 0.001). After precondition-
ing with a free-fall drop test, the mean activation force for 
cartridge AAI (n = 14) remained greater than for syringe AAI 
(n = 15; 22.55 ± 5.14 N versus 8.65 ± 0.63 N, respectively; 
Figure 4 example photograph showing the difference in injected dose and overall 
injection depth into ballistic gelatine (left, cartridge adrenaline autoinjector [AAi]; 
right, syringe AAi).
D
e
p
t
h
 
(
m
m
)
Actuating
position
Needle
length
Injection
depth
Maximum
depth
Syringe AAI (n = 5)
Cartridge AAI (n = 4)
***
***
***
**
0
5
10
15
20
25
Figure 3 comparison of maximum depth components for each device group under 
standard conditions. 
Note: **P < 0.01 vs syringe AAi, ***P < 0.001 vs syringe AAi
Abbreviation: AAi, adrenaline autoinjector.
E
s
t
i
m
a
t
e
d
 
m
e
a
n
 
i
n
j
e
c
t
i
o
n
 
v
o
l
u
m
e
 
(
m
L
)
Time (S)
0.30
0.25
0.20
0.15
0.10
0.05
0.00
0
.
0
0
0
.
5
0
1
.
0
0
1
.
5
0
2
.
5
0
Syringe AAI (n = 3)
Cartridge AAI (n = 4)
**
Figure 5 Mean volume injected during the first 2.5 seconds after activation.
Note: **P < 0.01 vs syringe AAi at 2.5 S
Abbreviation: AAi, adrenaline autoinjector.
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P , 0.001). However, after preconditioning with a static load 
of 400 N in vertical orientation, 100% (15/15) of cartridge 
AAI and 86.7% (13/15) of syringe AAI devices would not 
fire. Of the two syringe AAIs that could be activated, the 
force that was required had increased approximately fivefold 
compared with control AAIs (data not shown).
effect of denim on activation force  
and effective needle length
Under standard conditions, the mean activation force for 
cartridge AAIs remained unchanged in the presence of denim 
(n = 5; 23.48 ± 3.65 N compared with 22.43 ± 4.64 N in 
ballistic gelatine only; P = 0.596). This was similarly the 
case for syringe AAIs (n = 5; 8.22 ± 0.60 N compared with 
8.39 ± 0.66 N in ballistic gelatine only; P = 0.555).
After device activation into ballistic gelatine and denim, 
the effective needle length for cartridge AAI and syringe 
AAI was not significantly different compared with ballistic 
gelatine alone (P = 0.290 and P = 0.995, respectively; data 
not shown).
Visual inspection of the needle after removal from the 
ballistic gelatine after activation showed no damage or bend-
ing of the needle for syringe AAI. However, the needles 
from three cartridge AAIs (two from the ballistic gelatine + 
denim test and one from ballistic gelatine alone) were bent 
between 5° and 10°.
Discussion
To summarize, compared with the syringe-based AAI, the 
cartridge-based system of autoinjection appears signifi-
cantly more capable of consistently and rapidly delivering 
a clinically relevant dose to the desired i.m. region, through 
a combination of higher activation force, higher extrusion 
force and wider needle bore.
Under standard conditions, the force required to remove 
the safety cap from cartridge AAI was significantly less than 
that required for syringe AAI. The mean safety cap removal 
force was not changed for both AAIs following the free-fall 
drop test, although the static-load test resulted in a fourfold 
increase in the safety cap removal force of cartridge AAI. The 
activation force for cartridge AAI was significantly higher 
than that for syringe AAI prior to and following the free-fall 
drop test. A high activation and spring force for cartridge 
AAIs should ensure that a sufficient dose is delivered to the 
correct tissue compartment (i.m.) because of the resultant 
higher subcutaneous tissue compression and extrusion 
force. These forces may be inherently limited in the design 
of syringe AAIs through a combination of weaker points 
in the glass syringe, lower activation force and the differ-
ent activation technique required (ie, no swinging action) 
compared with cartridge AAIs. Thus, a lower activation 
force observed with syringe AAI may make the device easier 
to use, but could mean it is less sufficient in delivering an 
effective dose, as demonstrated in this study. However, to 
the best of our knowledge, there is currently no evidence 
Table 1 effect of free-fall and static load tests
Drop test Fully intact  
(n)
Broken internal components  
(n)
Damaged needle  
(n)
Syringe AAi 15 0 0
cartridge AAi 14 0 1
Static load test Fully intact  
(n)
Outer housing broken 
Activation not achieved  
(n)
Outer housing broken 
Increased activation 
force (n)
Syringe AAi 0 13 2
cartridge AAi 0 15 0
Table 2 effect of free-fall test and static load test on safety cap 
removal force
Sample  
number (n)
Mean ± SD  
cap removal 
force (N)
P-value 
Without preconditioning – standard conditions (control)
Syringe AAi –  
protection cap
20 16.58 ± 5.86 –
Syringe AAi –  
safety cap
15 20.23 ± 6.61 –
cartridge AAi –  
safety cap
15 9.56 ± 2.36 P , 0.001 versus   
syringe AAi –  
safety cap
Preconditioning – free-fall test
Syringe AAi –  
safety cap
15 21.07 ± 1.19 P = 0.690 versus  
control
cartridge AAi –  
safety cap
15 9.98 ± 0.68 P = 0.653 versus  
control
Preconditioning – static load test
Syringe AAi –  
safety cap
15 18.89 ± 2.203 P = 0.633 versus  
control
cartridge AAi –  
safety cap
15 38.39 ± 1.458 P , 0.001 versus   
controlJournal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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to suggest that this occurs in clinical practice or in real-life 
emergency situations.
The essential clinical feature of an AAI is the ability to 
reliably deliver a full i.m. dose of adrenaline after being car-
ried by the patient and subjected to mechanical stress over the 
shelf life of the AAI. Data from this pilot study showed 
that both cartridge and syringe AAI were able to withstand 
the free-fall drop test. However, a static load equivalent to 
40 kg resulted in damage not only to the outer housing of 
both types of device but more importantly also damaged 
the activation mechanism causing the vast majority to fail 
(100% of cartridge AAI and 86.7% of syringe AAI devices 
would not fire). The inconsistent results obtained after the 
static load test raises concerns regarding the reliability of 
cartridge AAIs, particularly with regards to the ability of the 
casing (outer housing) to withstand the stresses of modern 
living. The fact that the casings of both device types were 
damaged after a static load was applied suggests that there 
is a requirement for the use of stronger plastic materials in 
AAIs that do not go brittle over time, or a more robust design, 
as the AAIs must remain functional over the lifetime of the 
product and under all conditions. Because damage to the 
device may only be visible to a trained eye, it would normally 
only be revealed in a real-life situation, when a patient tries to 
administer adrenaline in an emergency, with potentially fatal 
consequences. Therefore, the use of additional carrying cases, 
such as the transparent plastic tube supplied with EpiPen® 
devices along with their cardboard cartons, may also provide 
greater protection than the sole cardboard carton packaging 
of Anapen® devices.
A final requirement of AAIs is the capacity to inject into 
the i.m. compartment through clothing. The presence of 
denim did not affect the mean activation force or the effective 
needle length of either device in this study. However, some 
needles of cartridge AAIs were bent after activation into bal-
listic gelatine, in the presence or absence of denim. The effect 
of a bent needle on the delivery of adrenaline into the correct 
tissue compartment requires further investigation.
Cartridge AAI also had a longer effective needle length 
than syringe AAI, and therefore is more likely to deliver to 
the correct i.m. tissue compartment. However, needle length 
alone is not sufficient to judge i.m. injecting ability in clinical 
practice,13 especially in the case of an obese patient with 
excess subcutaneous fat, or a patient wearing thick cloth-
ing. In addition, given the nature of these devices, it may be 
possible that devices with longer needles are not suitable for 
and are less likely to be used by small children.
It is important to note that the model used in this pilot 
study is a simplified simulation of clothed patients in the real-
world setting. Other limitations of this pilot study include: 
the small sample size used in some tests; the unknown effect 
of adding 16.6% extra volume of ink into the adrenaline 
solution of each device; the fact that these devices were no 
longer tamper-free (although the techniques adopted involved 
minimal tampering); the disadvantages of ballistic gelatine 
as a simulator of human tissue; the dose delivered was only 
measured over 2.5 seconds and not over 10 seconds as per 
the patient instructions for both AAIs (in order to avoid bias 
because the physical properties of layered gelatine blocks 
hampered interpretation of data beyond this timepoint).
The data presented here indicate that there are significant 
limitations in the design and quality of current AAIs available 
for the treatment of life-threatening anaphylaxis. Based on 
these small-scale tests, there is sufficient concern over the 
performance of the AAIs – in particular syringe AAIs – to 
call for a larger, more in-depth study including all devices, 
a variety of tissue simulants (including pig cadaver), three-
dimensional analysis to evaluate injection depth and ulti-
mately the development of standardized, validated assessment 
criteria of these putatively life-saving devices.
Conclusion
Data from this pilot-study, investigating the ‘real-world’ 
functionality and robustness of two currently available AAIs, 
indicate that cartridge AAI appears significantly more capable 
of consistently delivering a quick clinically relevant dose of 
i.m. adrenaline than syringe AAI. The syringe-based delivery 
system has inbuilt design limitations potentially making 
their dose delivery suboptimal. However, both cartridge 
and syringe AAIs are associated with shortcomings follow-
ing mechanical stress similar to that which is likely for the 
duration of their shelf life, and as such, may not be fit for 
lifesaving purpose. The findings from this study indicate a 
need for larger, more in-depth studies of the performance 
of AAIs, together with the development of standardized, 
validated assessment criteria for these devices.
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